Jan T. Poolman, Ph.D. Director, Bacterial Vaccines R&D

Slides:



Advertisements
Similar presentations
Target Product Profile and technical requirements Pre-tender Meeting Pneumococcal Vaccines under the AMC Unicef Supply Division, Copenhagen 26 August.
Advertisements

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.
Prevnar 13™ Pneumococcal 13-valent conjugate vaccine
Developing a Vaccine against Pneumonia, “The Captain of Death” -- Osler.
Meningococcemia: Epidemiology & Prevention Baylor College of Medicine Med-Peds Continuity Clinic Anoop Agrawal, M.D.
1 Pneumococcal Immunization in the Elderly. 2 U.S. Burden of Pneumococcal Disease in the Elderly Invasive disease (IPD = bacteremia, pneumonia with bacteremia,
Risk and prevention of pneumococcal diseases among patients in critical care setup Current evidence and guidelines…
Adriana Weinberg, MD University of Colorado Denver.
Streptococcus pneumonia (pneumococcus)
Vaccines and Related Biological Products Advisory Committee Meeting
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
Introduction of New vaccines Hib as an Example St. Petersburg Jun 2001.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease.
Hot Topics in Pediatric ID Robert J. Leggiadro, MD Chairman Department of Pediatrics Lincoln Medical Center Professor of Clinical Pediatrics Weill Medical.
Haemophilus influenzae type b
Evaluating Vaccine Effectiveness Using Serologic Assays
Carlos G. Grijalva, MD MPH Department of Preventive Medicine Vanderbilt University School of Medicine Nashville, Tennessee.
Vaccines and Related Biological Products Advisory Committee Meeting
Licensure of New Pneumococcal Vaccines For Adult Indications
CBER Perspective VRBPAC Meeting, November 16, 2010.
EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global epidemics Influenza viruses.
Basis for Developing a Pneumococcal Conjugate Vaccine for Adults George R. Siber, MD Executive Vice President and Chief Scientific Officer Wyeth Vaccines.
Indication for Otitis Media FDA Vaccine and Related Biologicals Advisory Committee Meeting May 21, 2002 Pneumococcal 7-Valent Conjugate Vaccine (Diphtheria.
1 1 Immunization Update 2011 Connecticut Immunization Teleconference April 19, 2011 William Atkinson, MD, MPH National Center for Immunization and Respiratory.
Splenectomy Vaccine Protocol PIDPIC Rationale Spleen clears encapsulated bacteria and infected erythrocytes Serves as one of the largest lymphoid.
Prevention of pneumococcal disease – What are the prospects? Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Allison McGeer,
Use of Immunogenicity Data to Assess Vaccine Effectiveness Cara R. Fiore, Ph D Microbiologist, Master Reviewer Office of Vaccines Research and Review Center.
Quality Assurance for Pneumococcal Assays in Europe Daniel Harrison.
“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.
Created byInformation Design A Mathematical Model for the Impact of the Conjugate Vaccine on S. pneumoniae Vaccine and Non-vaccine serotypes Robertino.
Modeling of the effect of pneumococcal conjugate vaccination on carriage and transmission of Streptococcus pneumoniae in Kenyan children John Ojal KEMRI-Wellcome.
Epidemiology of invasive pneumococcal disease in adults CDR Matthew R. Moore, MD, MPH Centers for Disease Control & Prevention U.S. Department of Health.
Immunogenicity of combined vaccines in infants Helena Käyhty, PhD National Public Health Institute Dept of Vaccines Helsinki, Finland.
Functional antibody activity as measured by opsonophagocytosis Sandra Romero-Steiner, Ph.D. Respiratory Diseases Immunology Laboratory.
1 Vaccines and Related Biological Products Advisory Committee Meeting November 18, 2009 Questions for the Committee Prevnar 13 Pneumococcal 13-valent Conjugate.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
Visibility of Vaccination and How Do We Improve?
Primary Immunogenicity Endpoints for New Infant Pneumococcal Conjugate Vaccines Vaccines and Related Biological Products Advisory Committee Meeting Lucia.
Cost-effectiveness of pneumococcal vaccination for older people: a study in five western European countries Ament A, Baltussen R, Duru G, Rigaud-Bully.
Scientific Basis for Review of Varicella Zoster Immune Globulin Products Blood Products Advisory Committee July 21, 2005 Dorothy Scott, M.D. OBRR/CBER.
CBER Introduction to license application: Aventis Pasteur license application for Meningococcal (groups A, C, Y, and W135) Polysaccharide Diphtheria Toxoid.
1 Vaccines and Related Biological Products Advisory Committee Meeting Prevnar 13: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM 197 Protein]
 Thomas F. Koinis, MD, FAAFP  Duke Primary Care Oxford  February 9, 2016.
September 16, 2014 Bedford Senior Center Joyce Cheng RN Community Health Nurse Bedford Board of Health.
Pneumococcal Vaccine Use Around the World: Successes and Challenges Adam L. Cohen, MD MPH Respiratory Diseases Branch, Division of Bacterial Diseases Centers.
1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.
1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,
C. Jillian Tsai, Ph.D. Department of Preventive Medicine
04/19/ Projected effectiveness of mass HIV vaccination with multi-dose regimens to be tested in South Africa Peter Gilbert Dobromir Dimitrov Christian.
Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immunogenicity of 13-Valent Pneumococcal Conjugate.
Pneumococcal Disease and Pneumococcal Vaccines Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory.
Guidelines for Vaccinating Dialysis Patients BY: DR. JONAIDI ASSOCIATE PROF. OF INFECTIOUS DISEASES.
Pneumococcal vaccination in adults: PCV13?.. PPSV23?.. both??
Haemophilus influenzae type b Using vaccines to measure disease burden: A Tale of Two Studies Presentation to PABIO 550 Diseases of Public Health Importance.
HPV Vaccines and Data Needed for Development of Recommendations in the United States Lauri E. Markowitz, MD Centers for Disease Control and Prevention.
Pneumococcal conjugate vaccine – Use of pneumococcal surface protein A (PspA) as carrier Dr Giovana Cappio Barazzone Centro de Biotecnologia
Vaccines and Related Biological Products Advisory Committee Meeting
* LABORATORY-BASED SURVEILLANCE OF S. PNEUMONIAE INVASIVE DISEASE (IPD) IN CHILDREN: SEROTYPE DISTRIBUTION AND ESTIMATION OF VACCINES COVERAGE B. V. M.
Vaccine Efficacy, Effectiveness and Impact
Bridging to Bridges in Vaccine Development: Challenges in Comparing Multi-Serotype Vaccines – Jonathan Hartzel, Merck.
The State of Pneumococcal Disease Prevention
Pneumococcal Disease Prevention in Children: Issues in the Era of PCVs
New Pneumococcal Vaccines
Pneumococcal conjugate vaccines: overview of a decade from Kuwait
The role of vaccination in preventing pneumococcal disease in adults
Addressing Pneumococcal Disease in Latino Communities
Pneumococcal Polysaccharide (PV) Vaccine Failures among HIV-infected Veterans Compared to Non-HIV-infected controls. Maria C. Rodriguez-Barradas, MD.
Cynthia Whitney MD MPH FIDSA Senior Subject Matter Expert, IHRC Inc.
*Includes partial introduction
Presentation transcript:

Jan T. Poolman, Ph.D. Director, Bacterial Vaccines R&D Pneumococcal Vaccine for Adults and Elderly Immunity, polysaccharides and conjugates VRBPAC November 17, 2005 Jan T. Poolman, Ph.D. Director, Bacterial Vaccines R&D

Adult pneumococcal immunization Polysaccharide immunization gives a substantial public health benefit mostly by impacting pneumococcal bacteremia This benefit occurs even though PPV immunization has a marginal impact on total burden of adult/elderly pneumococcal disease because immunization only once >65 yrs and because low impact on pneumonia

PPV Limitations PPV licensed with the indication « pneumococcal infection » Partial efficacy (appr. 50%) against invasive pneumococcal disease/bacteremia Low efficacy against pneumococcal pneumonia in >65 yrs. Precise efficacy unknown due to underpowered studies, and difficulty to diagnose Probably easier to protect against bacteremia as opposed to pneumonia No policy of revaccination, uncertainty of lowered responses upon revaccination (hyporesponsiveness)

PPV Revaccination « The limited data indicate older adults mount anti-CP antibody responses to revaccination, although the responses may be less than those to the initial injection of vaccine. If true, factors that may account for the hyporesponsiveness to revaccination include age, comorbidities, or … the initial vaccination. » From : Artz et al. Pneumococcal Vaccination and Revaccination of Older Adults. Clin. Microbiol. Rev. 2003, 16:308-318

PPV IPD Efficacy Clinical Effectiveness of pneumococcal vaccination in preventing invasive pneumococcal disease in observational studies in older adults From : Fedson D.S., Musher D.S. in « Vaccines », Ed. Plotkin S.A., Orenstein W.A. Pub. Saunders/Elsevier, 2004, pp. 529-588

Adult Pneumococcal Vaccine: Need for Improvement PPV : Substantial health benefit and marginal impact burden of disease Pneumococcal Pneumonia (30% of CAP) (nonbacteremic pneumococcal pneumonia) Cases/100.000/yr ( pneumococcal bacteremia) Invasive Pneumococcal Disease PPV impact PPV impact simulation: PPV administered at 65 years old; no revaccination Assumption: 30% of CAP is caused by S. pneumoniae PPV efficacy of 50% against IPD, 0% against pneumonia Adapted from Jokinen 1991 (Pneumonia in Eastern Finland in 1981-82) and Finish Ntl Register (Invasive pneumococcal disease in Finland in 1995-99)

PPV Efficacy Against Pneumococcal Pneumonia in Clinical Trials* Study, pub. yr. Population studied VE (95% CI) MacLeod, 1945 Military recruits (US) 84% (54%, 94%) Austrian, 1976 Young gold miners (S. Africa) 79% (65%, 88%) Smit, 1977 92% (49%, 100%) Riley, 1977 Young adults (PNG) 84% (<0%, 99%) Simberkoff, 1986 Veterans (US) <0% (<0%, 45%) Koivula, 1997† Elderly in community (Finland) 15% (<0%, 50%) Örtqvist, 1998 Elderly in community (Swed) <0% (<0%, 34%) Honkanen, 1999 † <0% (<0%, 20%) *Studies utilizing ≤ 60µg of each capsular polysaccharide and > 200 participants †PPV plus influenza vaccine cf. influenza vaccine alone

Why is the impact of PPV different in young adults versus elderly? Antibody level : impact of immunosenescence on the quantity of the immune (antibody) response Opsonophagocytosis : impact of immunosenescence on the quality of the immune (antibody) response Opsonophagocytosis : impact of immunosenescence on PMN functionality

Pneumococcal conjugate induced pediatric antibody levels and protection against IPD 0.18 µg/ml From : Jódar L. et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003, 21:3265-3272

23PPV Responses in Elderly Reverse cumulative curve for aggregated responses (11 polysaccharides pooled) -50 % IPD efficacy in elderly after PPV -50% of elderly achieve ~5 µg/ml anti-PS after PPV GSK Biologicals Unpublished data

Geometric Mean Concentrations (GMCs [µg/ml]) post-dose 1 (ELISA) in young adults (18-45years) and elderly subjects ( 65years) vaccinated with 23-valent PPV      = Significant n = 25

Geometric Mean Titers (GMTs [µg/ml]) post- dose 1 (OPA) in young adults (18-45years) and elderly subjects ( 65years) vaccinated with 23-valent PPV         = Significant n = 25

Key Messages Higher anti-PS antibody levels are needed to prevent IPD in elderly as compared to pediatric, this may relate to: IPD in adults usually associated with pneumonia; IPD in children is not Responses to PPV vs PCV Significantly decreased PPV responses (OPA) are observed in elderly vs young adults Immunosenescence in general

Pneumococcal Vaccination and Pneumonia PPV has demonstrated a clear impact on pneumonia in young adults PCV has demonstrated a clear impact on pediatric pneumonia

Pediatric 9-valent conjugate efficacy trials in South Africa, the Gambia Efficacy of vaccine serotypes against invasive pneumococcal disease: 83% (39-97) S. Africa 92% (44-100) the Gambia Efficacy of vaccine serotypes against bacteremic pneumococcal pneumonia: 61% (16-82) S. Africa 70% (31-80) the Gambia Efficacy of vaccine serotypes against pneumonia with proven bacteriology via lung aspirates: 73% (2-95) the Gambia Bacteremia without focus is easier to prevent than pneumonia

Targets for Improvement Develop vaccines that induce stronger anti-PS immune responses as compared to the existing polysaccharide vaccine Broaden the immunization age-range beyond the « one-shot at 65 » Overcome hyporesponsiveness that appears to be associated with PPV in order to allow revaccination

Keys for Licensure of PCV Immuno-noninferiority (OPA & ELISA) vs. PPV in adults/elderly : IPD/bacteremia Immuno-noninferiority (OPA & ELISA) vs. PPV in young adults : step towards pneumococcal pneumonia Response after revaccination is NI to response after primary vaccination